Companies In the News
Authors:
Date:
Business Wire: August 18, 2016 – GREENVILLE, NC, U.S.A. – Mayne Pharma (ASX: MYX) is pleased to announce it has acquired a portfolio of on-market dermatology foam assets from GSK for US$50.1 million. The foam assets include U.S. rights to Fabior and Sorilux, Canadian rights to Luxiq® and Olux-E® ,…
Authors:
Date:
PRNewswire: August 17, 2016 – BOSTON, MA, U.S.A. – Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) (“Juniper” or the “company”), a women’s health therapeutics company, today announced that a recently completed phase 2b clinical trial evaluating its 10% lidocaine bioadhesive vaginal gel, COL-1077, for…
Authors:
Date:
Business Wire: August 16, 2016 – REYKJAVIK, Iceland – Oculis announced today the close of a Series A financing round, led by Brunnur Ventures and Silfurberg. The new capital will support continued development of the company’s patented solubilizing nanoparticle (SNP) drug delivery platform and the…
Authors:
Date:
Business Wire: August 10, 2016 – LEXINGTON, MA, U.S.A. – TARIS Biomedical, a company developing powerful and targeted new treatments for millions of patients suffering from difficult-to-treat bladder diseases, announced today the initiation of a phase 1b clinical trial of TAR-200 (GemRIS™,…
Authors:
Date:
Business Wire: August 10, 2016 – REDWOOD CITY, CA, U.S.A. – Heron Therapeutics, Inc. (NASDAQ: HRTX), today announced that the U.S. Food and Drug Administration (FDA) has approved SUSTOL® (granisetron) extended-release injection. SUSTOL is a serotonin-3 (5-HT3) receptor antagonist indicated in…
Authors:
Date:
Business Wire: August 4, 2016 – JERUSALEM, Israel – Intec Pharma Ltd. (Nasdaq: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces the initiation of a new clinical development program for its Accordion…
